Singapore: +65-85097465 | India: +91-40-42023318
  U.S / Canada Toll Free: +1-866-259-4781
  Zimbabwe: +263-735539685, 773876488


Clinical Trial News

Roche initiates phase III trials for lampalizumab, first potential treatment for geographic atrophy (GA)

Roche has announced that phase III clinical studies have been initiated for lampalizumab, an investigational drug for geographic atrophy (GA), the advanced form of age-related macular degeneration...

Large prospective randomized trial confirms clinical benefit of Embryoscope® time-lapse system

The success rate of assisted reproduction was significantly increased by the use of revolutionary time-lapse technologyA study accepted for publication in the renowned scientific journal...

Merck discontinues clinical development program of tecemotide as a monotherapy in Stage III non-small cell lung cancer

Merck has announced that its biopharmaceutical division Merck Serono will discontinue the clinical development program of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide...

At four years, treatment effect maintained in more than two-thirds of patients who received Lemtrada in multiple sclerosis pivotal studies

Sanofi and its subsidiary Genzyme has announced positive interim results from the second year of the extension study of Lemtrada(TM) (alemtuzumab) for multiple sclerosis.

Data shows that nintedanib slowed lung function decline in patients independent of their lung function impairment at baseline

A pre-specified subgroup analysis from the two replicate Phase III INPULSIS™ trials, presented today in at the European Respiratory Society (ERS) International Congress in Munich, showed...

Phase III trials of pirfenidone show favourable and persistent treatment benefit on disease progression in patients with IDF up to 72 weeks

InterMune®, Inc. has presented the results of pooled analyses of data from three multinational, randomised phase III trials (ASCEND [Study 016] and CAPACITY [Studies 004 and 006]) that provide...

Poor recording of physical health and medication could be causing dementia trials to fail

Dementia trials could be failing because they all-too-often overlook the physical health of patients - according to new research from the University of East Anglia and Aston University.

AACR issues policy statement to urge FDA to provide oversight of high risk laboratory developed tests to protect patient safety and product innovation

The American Association for Cancer Research (AACR) issued a policy statement Tuesday, Sept.

James Lind Institute Newsletter
James Lind Institute Linkedin
James Lind Institute RSS
James Lind Institute Email Update
James Lind Institute Blog
James Lind Institute Facebook